Clinical trials
Ependymoma clinical trials
Below are recruiting ependymoma clinical trials, each written for real people, not researchers. We’re tracking 22 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05057702Recruiting
Personalized surgery-focused treatment plan for relapsed brain cancer
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
Los Angeles, CaliforniaAges 1–39 - NCT03750513RecruitingPhase 1
Tested improved radiation targeting for children with ependymoma
This early-phase study tests a more precisely targeted type of radiation for children with ependymoma, aiming to treat the brain tumor more accurately. It may help reduce how much healthy tissue gets radiation, and researchers are checking safety and best dosing.
Boston, MassachusettsAges Up to 22 years - NCT05151718Recruiting
Study of ependymoma treatment resistance in children
This trial looks at why ependymoma can resist (be harder to treat) after radiation or treatment. It studies children who are already being followed in specific existing programs, which may help researchers find better treatment approaches in the future.
ToulouseAges Up to 25 years - NCT02265770RecruitingPhase 2/Phase 3
Treatment plan for children with brain ependymoma after surgery
This trial tests different follow-up treatments for children with brain ependymoma after their initial surgery. Which treatment you get depends on how much tumor is left (if any) and whether the child can safely receive radiation and chemotherapy.
GrazAges Up to 22 years - NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT01356290RecruitingPhase 2
Anti-cancer blood-vessel treatment for relapsed childhood brain tumors
This trial tests a treatment that targets tumor blood-vessel growth to slow or shrink relapsed/progressive brain tumors in children. It may help if standard options are no longer working.
Chicago, IllinoisAges Up to 19 years - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT07226453RecruitingPhase 2
Metformin for recurrent PFA ependymoma
This trial tests if metformin can help treat a certain type of brain tumor called PFA ependymoma that has come back after surgery and radiation. It's for people ages 1 to 39 who are healthy enough for surgery or have tumors that can be measured on scans.
Birmingham, AlabamaAges 1–39 - NCT06161519RecruitingPhase 1/Phase 2
PLX038 for brain tumors with MYC or MYCN changes
This study tests a new drug called PLX038 for people with brain or spinal cord tumors that have certain genetic changes (MYC or MYCN) or have come back after treatment. The drug is given as an infusion and targets tumor cells. The study aims to see if the drug is safe and effective for different types of these tumors.
Bethesda, MarylandAges 18–120 - NCT05278208RecruitingPhase 1/Phase 2
Lutathera for high-grade brain tumors that returned or got worse
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Aurora, ColoradoAges 4–39 - NCT04185038RecruitingPhase 1
CAR T therapy through a catheter for pediatric brain tumors
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
Seattle, WashingtonAges 1–26 - NCT04374305RecruitingPhase 2
Study tests targeted treatments for NF2 tumors
This trial studies targeted medicines in people with neurofibromatosis type 2 (NF2) who have growing tumors on scans. The goal is to slow tumor growth and improve symptoms by testing different drug combinations in separate study groups.
Los Angeles, CaliforniaAges 12 years+ - NCT04648462Recruiting
Proton therapy planning for certain brain tumors
This study builds and tests how proton therapy planning could better protect the brain compared with standard radiation (photon therapy) for adults with certain brain tumors. It may help reduce radiation to sensitive areas like the hippocampus, with the goal of better long-term brain function.
Maastricht, LimburgAges 18 years+ - NCT04732065RecruitingPhase 1
ONC206 for certain brain tumors in children and young adults
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
San Francisco, CaliforniaAges 2–21 - NCT05106296RecruitingPhase 1
Chemo-immunotherapy with ibrutinib and indoximod for pediatric brain tumors
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
Augusta, GeorgiaAges 3–25 - NCT05259605Recruiting
Study uses brain tumor tissue and scans to track treatment outcomes
This is an observational study that collects and compares information from patients with primary brain tumors and their treatment results. It uses stored tumor tissue and brain scans to better understand outcomes using updated tumor classification methods.
InnsbruckAges 18 years+ - NCT05672043Recruiting
Study genetic risks in children with malignant brain tumors
This study looks at genetic (DNA/molecular) features of malignant brain tumors in children. It may help doctors better understand tumor risk patterns and guide future treatment planning.
Beijing, Beijing MunicipalityAges birth–18 years - NCT06193759RecruitingPhase 1
Immune cell therapy for malignant pediatric brain tumors
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
Washington D.C., District of ColumbiaAges 1–30 - NCT06779487Recruiting
Predicting memory changes from brain radiation
This study looks for biomarkers in your blood that might predict how radiation treatment affects brain function. The goal is to understand and possibly reduce cognitive side effects.
Mumbai, MaharashtraAges 5–39 - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT07424092RecruitingPhase 2
Virus injection for children with recurrent brain tumors
This trial is testing a virus called DNX-2401, which is injected directly into the tumor, for children and young adults with high-grade brain tumors that have come back or are hard to treat. The goal is to see if this virus can shrink or control the tumor.
UtrechtAges 1–25
Hear when a new Ependymoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Ependymoma trials by city
Studies with a site in or near these metro areas.
Ependymoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for ependymoma?
- Yes. Clin2 currently lists 22 recruiting ependymoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ependymoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ependymoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.